Through network pharmacology analysis, 23 key targets of the PSELNs against BC were screened, including PPARG, ESR1, FGF2, CAV1, etc. Gene chip analysis of key genes revealed that CAV1, FGF2, and PPARG exhibited lower expression in BC tissue samples compared to adjacent non-cancerous samples, whereas ESR1 showed higher expression. This evidence concerns the gene CAV1 and breast cancer.